Pixie Dust Technologies (NASDAQ:PXDT – Get Free Report) and Heyu Biological Technology (OTCMKTS:HYBT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Pixie Dust Technologies and Heyu Biological Technology, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Pixie Dust Technologies | 0 | 0 | 1 | 0 | 3.00 |
Heyu Biological Technology | 0 | 0 | 0 | 0 | N/A |
Pixie Dust Technologies presently has a consensus target price of $5.21, indicating a potential upside of 98.14%. Given Pixie Dust Technologies’ higher possible upside, analysts plainly believe Pixie Dust Technologies is more favorable than Heyu Biological Technology.
Insider and Institutional Ownership
Profitability
This table compares Pixie Dust Technologies and Heyu Biological Technology’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Pixie Dust Technologies | N/A | N/A | N/A |
Heyu Biological Technology | -453.55% | -6.43% | -4.43% |
Valuation and Earnings
This table compares Pixie Dust Technologies and Heyu Biological Technology’s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Pixie Dust Technologies | $5.18 million | 7.46 | -$14.45 million | N/A | N/A |
Heyu Biological Technology | $80,000.00 | 287.28 | -$270,000.00 | N/A | N/A |
Heyu Biological Technology has lower revenue, but higher earnings than Pixie Dust Technologies.
Summary
Pixie Dust Technologies beats Heyu Biological Technology on 7 of the 10 factors compared between the two stocks.
About Pixie Dust Technologies
Pixie Dust Technologies, Inc., a technology company, focuses on personal care and diversity, and workspace and digital transformation businesses primarily in Japan. It offers SonoRepro, an ultrasonic non-contact vibrotactile stimulation scalp care device; VUEVO, a series of directional voice arrival detection devices for individuals with deaf and hard-of-hearing; and kikippa, an acoustic stimulation device functioning as a desk-top speaker. The company also provides iwasemi, a sound-absorbing or sound-proofing material for architectural and interior design firms; hackke, a location positioning technology; KOTOWARI, a technology offering spatial analysis data; and magickiri, a planning services and monitoring service, which monitors human behavior and analyzes the customer's environment on the customer's behalf. In addition, it operates Pixie Nest, a membership forum, which hosts meetings and distributes information to facilitate solving social issues. The company was incorporated in 2017 and is headquartered in Tokyo, Japan.
About Heyu Biological Technology
Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.
Receive News & Ratings for Pixie Dust Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pixie Dust Technologies and related companies with MarketBeat.com's FREE daily email newsletter.